Risk adjusted net present value: What is the current valuation of Novartis’s XXB-750?
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.
What's Your Reaction?
